High-Yield Pearls for Management of Psoriasis with Therapeutic Updates

Conclusions

• Spesolimab (Spivigo) shows significant efficacy as a treatment for generalized pustular psoriasis (GPP) with FDA approval for subcutaneous maintenance dosing following initial IV administration.
• Over 90% of patients experienced fewer GPP flares at the high dose of subcutaneous Spesolimab compared to placebo over 48 weeks.
• Bimekizumab has expanded indications, demonstrating substantial efficacy for psoriasis and psoriatic arthritis, maintaining high response rates even after four years in difficult-to-treat areas.
• Bimekizumab has shown sustained improvements for patients with hidradenitis, with over 80% achieving significant reduction in inflammatory lesions by week 48.
• Ducravacitinib is recognized for its effective treatment of scalp psoriasis, with an expert consensus supporting its superior safety profile compared to traditional JAK inhibitors.
• There is no necessity for routine lab monitoring for patients receiving ducravacitinib, which may indicate a safer long-term maintenance therapy option.
• Recent studies have found an association between high ultra-processed food intake and active psoriasis, suggesting potential dietary influences on the disease.